Please Wait
Applying Filters...
menu
    • menu
    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-08-11

    Virtual Booth

    An Enquiry

    Menu

    Fisogatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Trial
    CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Trial

    06 Jan 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-pharmaceuticals-and-blueprint-medicines-initiate-phase-1b2-clinical-trial-of-fisogatinib-in-combination-with-cs1001-for-patients-with-hepatocellular-carcinoma-300981035.html

    PR NEWSWIRE
    06 Jan 2020
    Share Share
    CStone receives CTA approval in China to start Ph I trial for BLU-554
    CStone receives CTA approval in China to start Ph I trial for BLU-554

    29 Jan 2019

    //

    https://www.prnewswire.com/news-releases/cstone-receives-cta-approval-in-china-to-start-phase-i-trial-for-fgfr4-inhibitor-blu-554-cs3008-300785598.html

    29 Jan 2019
    Share Share
    Blueprint Medicines Announces Updated Data from Pha1 EXPLORER CTRLof Avapritinib
    Blueprint Medicines Announces Updated Data from Pha1 EXPLORER CTRLof Avapritinib

    15 Jun 2018

    // PRESS RELEASE

    http://ir.blueprintmedicines.com/phoenix.zhtml?c=253931&p=irol-newsArticle&ID=2354759

    PRESS RELEASE
    15 Jun 2018
    Share Share
    Blueprint Medicines Initiates VOYAGER Ph3 Clinical Trial of Avapritinib
    Blueprint Medicines Initiates VOYAGER Ph3 Clinical Trial of Avapritinib

    21 May 2018

    // PRESS RELEASE

    http://ir.blueprintmedicines.com/phoenix.zhtml?c=253931&p=irol-newsArticle&ID=2355440

    PRESS RELEASE
    21 May 2018
    Share Share